Outpatient Utilization of COVID-19 Treatments Under Emergency Use Authorization (EUA): A Simplified Descriptive Analysis for Paxlovid and other EUA Drugs

In this request, we monitored the utilization of outpatient COVID-19 treatment under emergency use authorization (EUA), by estimating the rates of outpatient COVID-19 treatment utilization and assessed the baseline characteristics of outpatient COVID-19 treatment users in the Sentinel Distributed Database (SDD) and the Rapid COVID SDD.

The study period includes data from December 22, 2021 to April 30, 2022. We distributed one request to three Sentinel Data Partners on July 1, 2022. These three Data Partners are a subset of the Rapid COVID SDD and include Data Partners with care setting information for laboratory data. We distributed a second request to two Sentinel Data Partners without care setting information for laboratory data. One of the two Data Partners is a subset of the SDD, while the other is a subset of the Rapid COVID SDD.